KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SAN FRANCISCO, Feb. 19, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs, today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of four weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 4179 4315#.
Dial-In Information
Live (U.S. / Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 41794315
About FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. We have capitalized on our extensive experience in fibrosis and hypoxia-inducible factor (HIF) biology to generate multiple programs targeting various therapeutic areas. Our most advanced product candidate, roxadustat, or FG-4592, is an oral small molecule HIF prolyl hydroxylase (HIF-PH) inhibitor, in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). Our second product candidate, FG-3019, is a monoclonal antibody in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. For more information about FibroGen, please visit www.fibrogen.com.
Contact Leanne Price FibroGen, Inc. 415-978-1200 [email protected]
